Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 22, 1999

View Archived Issues

Sumitomo applies for approval of amrubicin

Soltec enters strategic alliance with Mipharm

Dynal to provide component for Xcyte Therapies' activated T-cell product

NexMed initiates phase II trials of alprostadil cream in U.S.

Two new patents issued to Helix for drug delivery technology

Oxo Chemie reports promising data for immune therapeutic

Licensing opportunity from NIH: glycoprotein hormone superagonists

Allelix/NPS merger approved by stockholders, Canadian court

Vasomax progress updated by Zonagen

Pivotal studies begin for Emitasol

Statins as new approach to the treatment of bone loss diseases

Dexmedetomidine receives FDA marketing approval

Novartis discloses several new compounds for proliferative, inflammatory conditions

FDA is first agency worldwide to approve new fluoroquinolone for marketing

Cytotoxic polyheterocyclic compounds designed at Taiwan research institute

Meiji Seika presents heterocyclic inhibitors of platelet aggregation

New agents for diabetes in development at Otsuka

Pretreatment with complement inhibitor significantly reduces cardiac, brain damage following CPB

Selective, orally active factor Xa inhibitors designed by JT scientists

New FTase inhibitors from Schering-Plough with good cellular activity

MJ-355: a new K(ATP) channel opener with antihypertensive and cardioprotective effects

Scandipharm to become wholly owned subsidiary of Axcan

Acute and chronic effects of two new TZDs on glucose metabolism examined in rats

New agent for treating cocaine dependency in development at RBI

Major regulatory filings made for unique antidiabetic medication

Isis surprised by disappointing results in Crohn's disease study of ISIS-2302

Simultaneous E.U. and U.S. submissions for Combidex, a new MRI contrast agent

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 23, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 23, 2026.
Neurotrimin unveiled as marker in intellectual disability
BioWorld Science
Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease
BioWorld Science
Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...